Only 4 (1.8%) genotypes with the profi le 2DL1-,2DL3-,2DL2+ were observed in the population. The remaining 22.5% genotypes are present only one or twice The frequencies of KIR genes detected in our study are comparable to other Caucasian populations, while some differences with non-caucasian population are observed.
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INFECTION RELATED MORTALITY IN KIR-LIGAND MISMATCH IN UNRELATED ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION
M Schaffer, O Ringdén, M Remberger, H-G Ljunggren, K-J Malmberg. Div of Clin. Immunology, CAST, CIM, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.
Natural killer cells (NK) interact with MHC-class I molecules on target cells. In humans, NK cells are negatively regulated by killer cell Ig-like receptors (KIR) recognizing groups of HLA class I alleles. KIR ligand mismatch in the graft versus host GVH direction is associated with improved survival in haploidentical, T-cell depleted hematopoetic stem cell transplantation (HSCT) for AML. The role for KIR-ligand mismatch in unrelated T-cell replete HSCT is more controversial. While some centers report benefi cial effects of KIR ligand mismatch on transplantation related mortality (TRM) and survival, data from our center could not confi rm such effects. In contrast, we observed increased infection related mortality and inferior survival for patients receiving KIR ligand mismatched grafts. Here we report an update of this analysis including totally 238 patients with hematological malignancies receiving grafts from an unrelated donor. Allele level typing was performed for all classical HLA loci. The selected patients were matched at allele level for HLA-A, -B and DRB1. KIR-ligand match/ mismatch (208/30) was predicted from the high resolution typing of HLA-C. KIR-ligand mismatch was associated with increased TRM (p<0.01) leading to a decreased overall survival (p=0.007). Relapse did not differ signifi cantly between the groups. The results were identical when only patients with myeloid malignancies were included in the analysis (n=155).
It seems clear that KIR ligand mismatching may not be used as a criteria for donor selection in unrelated HSCT at this stage. Further studies are warranted to defi ne the conditions that help to preserve/promote NK mediated graft-versus-leukemia effects. Such studies should focus on the role of KIR alleles (activating and inhibitory) as well as phenotypic assessment of the NK repertoire that mature in the recipient.
New Developments and Techniques
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THE
RELEVANT SIGNIFICANCE OF SOME WBC SUBPOPULATION RATIOS B Pantelis, 3rd IKA Hospital, Biopathology Department, Athens, GREECE The signifi cance of some ratios is obvious if we consider we usually report percentages of WBC subpopulations in the clinical fi eld. But what happens when we have to deal with individual ratios of subpopulations of WBCs? For example, the ratio of Band Forms to Lymphocytes was introduced by us as a means of describing the level of clinical acuity (Acuity Ratio) (AR) . Although this cannot be the case in every clinical situation, there are some instances where a lowering of lymphocytes coincides with a rise of stab cells at the beginning of an acute condition and later on, the decrease of band cells with the absolute increase of lymphocytes, especially the activated forms of them. This phenomenon creates a progressive diminution of AR. We speculated that this loss of acuity and the resulting transformation to chronicity cannot be described simply by a single percentage or a concentration of a certain subpopulation and, if this is true, why not try and other ratios and see what are their diagnostic or prognostic implications.
We examined a set of ratios between subpopulations: Stab cells to Neutrophils (SN), Stab cells to Lymphocytes, Stab cells to monocytes (SM), Neutrophils to Lymphocytes (NL). We present combined data from several different works, either comparing patients with fever (F) to non fever patients (NF), or groups of patients categorized by glycaemic levels -Noromoglycaemic (N), Hyperglycaemic (HG), Diabetic (DM)-or from a general sample of patients divided by clinical severity. Subpopulations were estimated by a combination of data of an hematology analyzer (SYSMEX) and differential counting. SN and AR differed signifi cantly between F diseases and NF acute diseases, these differences being unaffected by gender. When we discriminated for 3 degrees of clinical severity F patients differed signifi cantly in AR, SN and SM from NF patients only at medium severity (hospitalized patients) while at the minimum severity (outpatients) no change was established. At maximum severity (intensive care) the existing difference was not confi rmed statistically due to data paucity.
In NF patients the 3 glycaemic levels disturbed the SN while this was not the case in F patients. The SN of F patients was found three fold the value of NF patients at the normoglycaemic level and two fold at a medium hyperglycaemic level, while it was unaffected at maximum hyperglycaemic level (DM). The AR showed a similar pattern of differences between F and NF patients in different glycaemic levels although there was no such tremendous difference. A signifi cant escalation of AR was seen between glycaemic levels of NF patients, while in F patients the highest value was noticed in HG. Generally the glycaemic level differentiated the NL, SM, SN and AR in both sexes, considered separately, and between sexes of the same level signifi cant differences were established only in DM.
Although at the moment no clinical application can be established, these fi ndings suggest to us that separate subpopulation ratios are worth to be considered in research of biological laws with vast samples.
HLA HIGH RESOLUTION TYPING: LIMITS OF SSP AND SBT TECHNIQUES / SEARCH FOR NEW STRATEGIES
Agnès Moine, Cosima Semoun, Martine Diaz, Sylvette Hammerer, Jean Claude Bensa, Dominique Masson EFS Rhône Alpes, Site de Grenoble, France A theoretical study was initiated to estimate the rate of ambiguities remaining after high resolution typing obtained by two major techniques : SSP and SBT on A, B, Cw and DRB1 loci.
More than 25000 different SSP patterns (Genovision SSP kits) and 310 000 exons 2 and 3 allelic combinations have been recorded. Among them, and because of the high polymorphism of the HLA complex , some allelic typings could not be defi nitively established.
The problems found in homozygous typings were mainly -Alleles with a SSP pattern included in other allelic patterns , which could generate a misinterpretation of rare alleles -Alleles with an identical exon2+3 sequence, including 12 null and 15 expressed alleles which could not be distinguished from each other. In these cases, other parts of the gene sequence, such as exons 1, 4, should be investigated.
In heterozygous combinations, the major cause of ambiguity came from DNA motifs exchange between alleles. The estimate rate of ambiguities was : HLA genotyping always starts with a fi rst step of DNA extraction usually from peripheral blood. The clinical histocompatibility laboratory normally requires not only a highly purifi ed solution of genomic DNA but also a substantial yield to allow typing techniques that require large amounts of DNA (PCR-SSP) and to allow archiving for further testing.
The Abbott m1000 is an automated system designed for the purifi cation of both DNA and RNA from clinical specimens in a medium to high workfl ow laboratory. Automation starts with the blood primary collecting tube identifi ed by barcodes and all the preparation processes are conducted in a single tube with no user intervention. Reagents are in a 96 prep format based on detergent and chaotropic salt chemistries associated to nucleic acid affi nity magnetic microparticles. The input volume of starting material and eluate output volume can be user-designed so that sample concentration better suits downstream applications.
In a year of use in our laboratory, we processed 9500 samples with the Abbott system with an input volume of 400ml of whole blood (or buffy-coat for low leucocyte count samples). The median yield of the DNA solution was 18mg (SD ±10) eluted in 200ml of distilled water. This corresponds to an average concentration of 90mg/ml. Purity analysis measured by the relation A260/A280 had a median value of 1.71±0.2.
The DNA solution obtained is suitable for PCR-SSP typing in the typical technique concentration range as well as multiplex PCR amplifi cations and rSSOP. Following manufacturer's protocols we found no cross contamination and a low rate of preparation failures.
In summary, the Abbott m1000 nucleic acid extraction workstation is a valuable system for the automation of sample preparation in the high workfl ow laboratory. Furthermore, it can be adapted to the HLA laboratory needs, for example automating PCR plate set-up for routine protocols.
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A QUANTITATIVE AND COST-EFFECTIVE METHODOLOGY FOR HEAT SHOCK PROTEIN 70 INVESTIGATION Rose Njemini, Christian Demanet, and Tony Mets Heat shock proteins (Hsp) are present in cells of all organisms and the genes encoding them are highly conserved. These proteins are typically regarded as intracellular proteins although studies have shown that they can be secreted in to the peripheral circulation. Under normal physiological conditions, Hsp are expressed at low levels and play diverse roles as molecular chaperones preventing protein denaturation. A variety of stressful stimuli, including hyperthermia, physical stress, and various disease states, induce substantial increase in intracellular Hsp synthesis. Several studies have shown the expression of Hsp, especially Hsp 70, during clinically relevant situations, and evidence is mounting that the ability to survive and adapt to severe systemic physiological stress is critically dependent on the ability of cells to mount an appropriate compensatory stress response. The need for a simple assay for determining Hsp 70 in cells has emerged with the increasing interest in therapeutic manipulation of Hsp for clinical trials. In this study we have developed a new technique for the investigation of intracellular Hsp 70. This cell lysate immunometric assay (CLIA) uses a combination of two distinct monoclonal antibodies that recognize different epitopes on the Hsp 70 molecule. A recombinant human Hsp 70 was used as the standard material. The detection range of the CLIA was 4 -4000 ng/mL. The intra-and interassay coeffi cients of variation were, on average, 5 and 12, respectively. The recovery varied between 81% and 116%. The Hsp 70 levels assayed after serial dilution of cell lysates varied linearly with dilution (between 97% and 120%). The reliability of the CLIA for the detection of Hsp 70 was assessed by comparing the values determined by fl ow cytometric procedure; these two sets of values showed a highly signifi cant correlation (r=0.896, p<0.0001), indicating that the two methods are comparable. In conclusion, the described CLIA can be considered as a low-cost alternative of the fl ow cytometric technique that may be important to address issues related to Hsp70 secretion in clinically relevant conditions.
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A TECHNICAL ADAPTATIONS FOR THE MICROSATELLITES STUDY IN BLADDER CARCINOMAS
Victoriano J. Leon, Manuel Urrutia1, Javier Garcia1, Alberto J.Leon2. Serv. Bioquímica. 1 Serv. Urologia, Hospital Universitario de Salamanca (Spain). 2 Laboratorio de Pediatria e Inmunologia, Universidad de Valladolid (Spain) Introduction: Microsatellite analysis has shown promise as a highly sensitive tool for the study of differences inter cells populations( primary and recurrent cancer) and susceptibility for some pathologies (certain immune-mediated as diabetes and immune-neurological diseases).
Material and methods: We select blood, tissue of superfi cial bladder carcinoma and exfoliated cells of urine samples, as a source of DNA were collected from 10 patients, and 10 controls. DNA was extracted with DNAzol. A whole genomic amplifi cation ( DOP-PCR, Roche) of exfoliated cells were necessary to standard the DNA quantities of samples.
We used a diagnostic set of polymorphism microsatellite markers, D4S243, D9S162, IFNA, D9S171, D9S747. PCR was performed as indicated by manufacturer of Taq-polymerase (BioLine) . Polymerase chain reaction products were separated on denaturing 10% acrylamide-urea gels, photographed and the images were analysed with the program GelQuant (AMPL Software).
Results: They were not differences when comparing the microsatellites of urine samples and blood in the group control. Signifi cative differences were found among the same patient's samples in at least three of the microsatellites studied.
HIGH RESOLUTION HLA-DQA1 TYPING BY INNO-LIPA.
Ilse De Canck1, Lia Verdoodt1, Hilde De Henau1, Nancy Vande Casteele1, Miriam Bläser1, John Harvey2, Tom Van De Casteele1, Linda Celis1, Gonda Verpooten1 1Innogenetics NV, Gent, Belgium, and 2H&I Laboratory, National Blood Service, Bristol, UK A reverse hybridization assay, INNO-LiPA HLA-DQA1, has been developed for high resolution typing of HLA-DQA1 alleles. In order to identify the HLA-DQA1 alleles specifi cally in homozygous or heterozygous combinations, detection of polymorphisms in exons 1, 2 and 3 is required. Since this region is too large to amplify with one primer pair, a duplex PCR has been optimized, amplifying exon 1, and exons 2 and 3. After PCR, the amplicons are hybridized with 35 specifi c probes, immobilized on a single INNO-LiPA strip. For all HLA-DQA1 alleles described until October 2004 (IMGT-HLA database, release 2.7), 100 % theoretic allelic resolution is obtained.
In order to validate this assay, 75 samples previously DNA typed for HLA-DQA1 will be typed by INNO-LiPA HLA-DQA1. Possible discrepancies will be further analyzed by sequencing. The results will be presented.
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IMPROVED HLA-B RESOLUTION BY RESOLVING BW4/BW6 AMBIGUITIES Ilse De Canck1, Robert E Cirocco2, Frank Pollifrone1, Chris De Beul1, Gonda Verpooten1. 1Innogenetics NV, Gent, Belgium, and 2Univ. of Miami, FL, USA.
The INNO-LiPA HLA-B Update kit was designed for allele group resolution, but some ambiguities remained. To resolve the main ambiguities, ie, those involving Bw4 and Bw6 alleles, a Bw4 primer pair was added to the kit (INNO-LiPA HLA-B Update Plus). The Bw4 primer pair specifi cally amplifi es exon 2 of the Bw4 alleles and the amplicon hybridizes with the probes of the current INNO-LiPA HLA-B Update strip 1.
To study the effi ciency of this updated kit, 50 samples that had been SSP typed positive for Bw4 and Bw6, were selected and re-analyzed by using the INNO-LiPA HLA-B Update Plus kit. Of those 50 samples, 43 (86 %) were resolved at allele group level after generic HLA-B typing. The remaining 7 samples were ambiguous and were further tested with the new Bw4 primer pair. All allele group ambiguities were resolved as shown in the In our Center we are developing a simple method to determine antigenic differences between donor and recipient before hematopoietic stem cell transplantation, not defi ned by current typing strategies. The evaluation of the "in vitro" effects of these differences causing alloreactivity might be important for the prediction of "in vivo" Graft-versus-Host reactions. In our study, the ELISPOT technique was applied to measure the frequency of interferon-g (IFN-g) producing cells from a responder after stimulation with an HLA-mismatched individual. As a fi rst approach, peripheral blood mononuclear cells (PBMC) from healthy donors were used as stimulator (S) and responder (R). R PBMC were co-cultured for 72 h at different concentrations with irradiated S PBMC both in ELISPOT plates and in U-bottom 96 well plates. In this last case, cells were transferred to the ELISPOT plates after 48 h. Several controls were set up to test the infl uence of irradiation and medium on cytokine release and autoreactivity. Preliminary results showed that IFN-g spots (100/well) were clearly revealed using 2X105 R/S cells/well, only when the stimulation started in the U-bottom plate. While autoreactivity was not detected at all, irradiation did not avoid the production of cytokine by S cells. Experiments are in progress to optimize the method, measuring IFN-g secretion only from R cells. Our strategy defi nes HLA-B alleles by the cross-information of groupspecifi c amplifi cations and specifi cities of probe hybridizations. Our approach next to group-specifi c primers and probes co-amplifi es another gene (beta-globin) as internal control. Therefore monitoring of both amplifi cations is achieved by application of two sets of FRET probes, one specifi c for the HLA-B locus (LC-Red 640) and the second set (LCRed705) for the detection of the internal control gene. In each tube HLA-B probes show different mismatches with the amplifi ed alleles depending on their sequence, giving 2-5 differences for each tube. By the analysis of the melting curve pattern of all the HLA-B probes, a specifi c genotyping for each sample can be raised with a medium-low fi nal resolution. After successfully set up the approach by testing 250 samples, we plan to type additionally two hundred clinical samples that were previously typed by standard PCR-based methods. In all this pre-typed samples, results were concordant. Moreover, even a reduction in ambiguous results was obtained when using this new approach. In fact, our proposal for defi ning HLA-B alleles by real-time PCR with FRET probes was found faster and less cumbersome than PCR-SSP or PCR-SSO techniques currently used in HLA genotyping.
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HAPLOTYPE SPECIFIC EXTRACTION VERSUS GROUP SPECIFIC AMPLIFICATION
Milena Vraná, Marie Dobrovolná Inst.of Hematology and Blood Transfusion, Prague Czech Rep.
Haplotype Specifi c Extraction (HSE) is one of the methods used for allele separation prior to Sequencing-Based Typing (SBT) to resolve ambiguities in heterozygous samples.
We compare here the HSE method using HaploPrep HLA-B kit (GenoVision Inc.) with the separation by Group Specifi c Amplifi cation (GSA) using Allele SEQR-B GSA kits (Atria Genetics, Inc.). A cohort of 42 ambiguous samples typed by SBT (exon 2, 3 and 4) with 111 possible results was examined. 26 of the ambiguous results can be discriminated by SBT after allele separation. HSE is able to separate alleles in all 26 samples, GSA in 21 of them. HSE enables to sequence longer DNA fragment, as against shorter PCR product of GSA (exon 2 and 3 only). Special equipment (GenoM-6 robot) and changes in a following SBT protocol is required for HSE contrary to GSA.
The HSE method was tested in 11 samples. Only in fi ve of them a quantity of a posterior PCR product (after an increasing the number of PCR cycles as recommended) enabled sequencing of exon 2, 3 and 4 of tested locus. The SBT data was of a good quality without any evidence of the second allele.
Conclusion: The HSE can lead to overall better resolution of a consequential SBT (at least in tested cohort), but a robustness of the method is necessary to optimise. To confi rm the advantage and disadvantage of reference strand mediated conformation analysis RSCA system in HLA-A and B matching for hematopoietic stem cell transplantation.
124 DNA samples (86 for HLA-A, 92 for HLA-B and 54 were overlapped) were extracted from peripheral blood cells. HLA-A and B loci were typed both by RSCA and PCR-SSP. The ambiguous results were further confi rmed by DNA sequencing.
The results demonstrated that 81/86 and 86/92 cases could be designated defi nitely for HLA-A and B samples, respectively, and 33/86 and 67/92 could be typed to allelic level for HLA-A and B samples, respectively. In addition, 3 cases could not be detected by RSCA for their poor PCR results. 8 ambiguous results were confi rmed by DNA sequencing which indicated that the databank for RSCA should be improved and RSCA could fi nd new alleles. The replication rate of RSCA was 100%, and for PCR-SSP typing results, there were about 10% samples needed to be typed for 1-3 times to confi rm their types.
The results indicated that RSCA had some advantages compared with PCR-SSP typing method, such as sensitive, accurate, high resolution good repetition, can fi nd new alleles, etc. But time-consuming for single case, higher DNA quality requirement and incomplete database should be further improved.
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SEQUENCE BASED TYPING OF DQA1 EXONS 1 TO 4
Christina EM Voorter, Eva MT Mulkers, Eva van Engelen, Ella M van den Berg-Loonen Tissue Typing Laboratory, University Hospital Maastricht, Maastricht, The Netherlands Typing of DQA1 by sequencing has been a challenge due to a 3 nucleotide deletion in exon 2 in half of the alleles. Furthermore, 19 of the 28 alleles cannot be identifi ed on basis of exon 2 alone, but additional information is needed from the other exons. We have developed a sequencing strategy for exons 1 to 4, enabling identifi cation of all DQA1 alleles by SBT.
Exons 1 to 4 were amplifi ed separately with primers located in the 5' UT region and the introns. Elucidation in a previous study enabled the design of gene-specifi c primers. Heterozygous sequencing was performed in the forward direction. The combined sequences were used for automatic allele assignment. Exon 2 was sequenced reverse when the two DQA1 alleles belonged to two different groups, one with and one without deletion. The 5' part of exon 2 up to the deletion, obtained by forward sequencing, was combined with the 3' part obtained by reverse sequencing.
The method was validated by sequencing exons 1-4 of 19 selected individuals with known high resolution DQA1 typing. The individuals were all heterozygous for DQA1 and were selected in such a way that all allele groups were tested in combination with the other groups. In total 14 different DQA1 alleles were identifi ed in the panel and all of them were correctly sequenced heterozygously in all combinations. In addition 20 quality control samples from the UCLA exchange were typed for DQA1 by this method and all reported results were correct. Of the 39 samples sequenced for DQA1, only 2 could be directly typed to the 4 digit level by analysis of exon 2 alone. In 24 cases (62%) exon 3 sequences were needed, in 3 cases (9%) the sequence of exon 1 was required and in 10 cases (26%) analysis of both exons 1 and 3 was necessary for unambiguous 4 digit typing.
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UTILIZATION OF THE SEQUENCE BASED TYPING METHODS FOR HLA CLASS I AND CLASS II ALLELES IN GUANGZHOU CORD BLOOD BANK
Li Yan, Tang Xue-wei, WU Jie-ying, Yuan Si-min, Yang Xin, Huang Yi-ning, Liao Can. Guangzhou Cord Blood Bank, Guangzhou Maternal and Neonatal Hospital, Guangzhou 510180, China
The sequence-based typing (SBT) method provides the most accurate and complete identifi cation of HLA genotypes. From Dec. 2003, we use this method to type the cord blood samples collected in Guangzhou Cord Blood Bank.
The SBT method described utilizes an ABI Prism 3100 DNA Analyzer. Usually, we can get Class I sequences encompassed exon 2, 3, and 4 for HLA-A or -B loci for 16 samples in a sixteen-hour period with HLA AlleleSeqR Based Typing Kits (Forensic Analytical, Hayward, CA, USA). For HLA-DRB1, the exon 2 was analyzed with three sequencing reactions -one forward, one reverse and one specifi c for Condon 86. So, we can get results for HLA-DRB1 for 64 samples each time. Normally, we get SBT results for HLA-A, -B and -DRB1 loci for 24 samples every 5 working days. This is just fulfi lled the speed to store cord blood in our cord blood bank. Up to the present, more than 800 samples were typed by SBT.
The high cost and the low data analyze speed are two main problems for SBT method. The cost was decreased with 3/4 folds dosage of sequencing reagents. Using Assign SBT TM 3.0 software, the bottleneck for the sequencing data process has been overcome.
FLOW CYTOMETRIC DETECTION OF COMPLEMENT-ACTIVATING HLA ANTIBODIES
Nils Lachmman, Constanze Schönemann*, Abdulgabar Salama *Charité -Universitary Medicine Berlin constanze.schoenemann@charite.de Flow cytometry (FC) is increasingly used for HLA antibody (Ab) detection and donor-recipient crossmatching. Most of available FC techniques do not discriminate between complement-and non-complement-activating Abs. However, the clinical relevance of non-complement-activating Abs is discussed controversially. Therefore, many laboratories still use the conventional complement-dependent microlymphocytotoxicity crossmatch (CDC-XM) alone or in combination with FC.
We describe a novel fl ow cytometric complement-dependent cytotoxicity crossmatch assay (FC-CDC-XM) that clearly identifi es complementactivating Abs. We used fl uorescence-conjugated anti-CD3 and anti-CD19 monoclonal Abs for the identifi cation of T and B lymphocytes and propidium iodide (PI) for the discrimination of complement-damaged and vital cells. A total of 39 sera with specifi c HLA class I (n=30) or class II (n=9) Abs as well as 15 sera without any HLA Abs were tested using FC-CDC-XM. A sum of 180 crossmatches were performed in parallel with FC-CDC-XM and standard CDC-XM. The concordance between FC-CDC-XM and CDC-XM was 87% (157/180). FC-CDC-XM was able to correctly identify all Abs tested as specifi c to HLA class I or class II. In combination with standard fl ow cytometric crossmatching (FCXM) that detects IgG Abs regardless their capability of binding complement, FC-CDC-XM was able to discriminate between complement-and non-complement-activating Abs.
The new FC-CDC-XM is more sensitive and more objective than the standard CDC-XM and can be used for pre-and post-transplant diagnoses and detection of other cytotoxic reactions. 
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INCREASING THE RESOLUTION OF SSO TYPING METHODS USING NOVEL PROBE DESIGN
Jar-How Lee, Lindley Blair, Katsuyuki Saito, Jennifer Ng*, Ting Tang*. One Lambda, Inc., Canoga Park, CA., *NMRC, Rockville, MD, U.S.A. Molecular typing of HLA genes is essential for matching of unrelated stem cell recipients. While there have been signifi cant technical improvements in typing methodologies, the complexity of HLA genes still presents cis/ trans ambiguities that require laborious re-typing to resolve. Although there are several approaches for ambiguity resolution, such as SSP, secondary group-specifi c amplifi cation followed by SSO, or direct sequencing, these techniques are laborious, time consuming and costly. Conventional SSO methods produce the highest amount of cis/trans ambiguities due to the limitation of only one probe per target region. The most common ambiguities seen are: DRB1*0301,*1101 vs. DRB1*0308,*1307 or A*0301,*2501 vs. A*3204,*6601 which all require secondary testing.
We developed a novel probe design to reduce the number of cis/trans ambiguities in SSO. Our method involves the development of unique probes that interrogate two or more target regions simultaneously. These probes detect alleles by recognizing multiple non-continuous polymorphic sequences on the target amplicons. The probes do not require any special assay conditions, and their utilization leads to signifi cantly fewer cis/trans ambiguities thereby reducing the need for secondary typing methods. For example, in a series of 3900 random donor typings, HLA-A supplemental typing has been reduced from 1% to 0.2% after testing with this unique probe design system. HLA-B supplemental typing was reduced from 10% to 2.5%, and HLA-DRB1 supplemental typing was reduced from 25% to 0.8%. In conclusion, our novel probe design provides a higher resolution result with fewer ambiguities while retaining the high throughput of an SSO method.
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RESOLUTION OF AMBIGUOUS HLA HETEROZYGOTES BY REAL-TIME PCR
Malcolm McGinnis, David Sayer, Damian Goodridge, Jason Stein, Pete Krausa Atria Genetics, South San Francisco, CA, USA Conexio Genomics, East Fremantle, Western Australia A major consequence of the continual increase in allelic variability of HLA genes is a corresponding increase in the number of ambiguous heterozygote combinations that are encountered in routine typing situations. Ambiguities can be due information that is located outside the primary region of analysis or they can be due to heterozygous motifs for which the cis/trans relationship needs to be defi ned. Among the common methods for resolving such ambiguities are SSP-PCR, group-specifi c amplifi cation (GSA) followed by direct DNA sequencing, use of group-specifi c sequencing primers with heterozygous PCR products (GSSP), and single molecule amplifi cation from limiting dilution resulting in hemizygous PCR products. In this study, we describe a modifi ed SSP-PCR approach using Real-Time PCR, allowing simultaneous PCR amplifi cation and detection of relevant polymorphic motifs. Based on the 5´ nuclease activity of Taq polymerase and Fluorescent Resonance Energy Transfer (FRET) probes, TaqMan PCR is ideal for routine HLA typing situations. This approach eliminates the need for post-amplifi cation processing such as agarose gel analysis or probe hybridization, both of which require additional interpretation/typing steps. These TaqMan ambiguity resolution reactions allow faster typing times but also reduce the possibility of interpretation problems through softwareassisted data interpretation directly from the Applied Biosystems Real-Time 7500 System. The assay design can also take advantage of multiplexing and color-coding of the detection reactions, further minimizing typing mistakes due to sample mix-ups or gel-loading errors. With the appropriate selection of Real-Time SSP-PCRs, all common HLA typing ambiguities can be resolved quickly and easily. ELISA HLA antibody screening has been used for 3 years in our laboratory for patients waiting for organ transplantation. Since improvement in time orPganisation can be obtained with Luminex screening method, a comparative study between ELISA and Luminex for HLA antibodies detection has been performed on randomly chosen sera from patients waiting for renal transplantation. We compared reactivity of the two LUMINEX assays for anti HLA class I and class II antibodies detection with ELISA LAT-M: Lifematch (Orchid diagnostics, Bionobis) (n=164) and Labscreen (One Lambda, Ingen) (n=88).
Results are presented on the following With Labscreen, 6 results were excluded because of a high background negative control. A monoclonal IgM anti-HLA class I antibody was positive with LAT-M, negative with Lifematch and non validated (high background) with Labscreen.
All ELISA positive-LUMINEX negative results were found negative with lymphocytotocity method. Ten were tested with Lifematch identifi cation: 8 were confi rmed negative and 2 were positive.
Since discrepant results were not attributed in all cases to the sensitivity of the methods, further studies must be performed before choosing the most accurate anti-HLA antibodies detection method. Sequencing based typing (SBT) is the gold standard in HLA-typing. The most time consuming and error prone part of SBT is data-analysis. We improved our software package which now combines all sequences of one sample to a conclusive HLA-typing. This includes the automatic assembly of sequences from different regions (e.g. exons 2, 3, 4 and introns for class I), the heterozygous sequences as well as those obtained after allele separation (GSAP, GSSP) and, when available, sequences of additional regions. All sequence information available will be used to its full extend. Independent of the equipment used, all sequences can be processed.
SBTengine also will guide through the typing process: in case of ambiguities, it will report which GSAP or GSSP reactions should be applied to resolve the ambiguities.
Analysis is highly automated: typings will be performed automatically; only when base calling cannot be determined with high reliability, the sequences have to be inspected manually. In case of uncertainties, multisequence analysis will assist in obtaining the correct base call, making use of the high reproducibility of sequence patterns, which are recognized by the software.
SBTengine also contains export functions, which will create an XML output fi le, containing all relevant SBT information, including allele assignment and the sequences. These fi les can easily be used to import the data into hospital data management system, for data exchange, and for direct submission of SBT data to the IHWG workshop.
Demo versions of SBTengine® may be downloaded from http://www. genomediagnostics.com In order to restore HLA-B*1302 expression in ANDO-2 cell line by gene transfection, a cDNA had to be cloned. An EBV cell line (M-32) was selected that was typed for HLA locus B as HLA-B*1302, 1401. After mRNA isolation from M-32, cDNA from HLA-B locus was selectively amplifi ed with a pair of primers. The 5′ primer was common for HLA-A, B and C locus and the 3′ was specifi c only for HLA-B locus and located 349 bp downstream in the 3′ untranslated region. The PCR product was cloned into pcDNA 3.1 vector. A cDNA clone was isolated and sequenced. This cDNA clone exactly matched HLA-B*1302 gene (AJ 295278) in the sequence of all exons (1-7) and also in the 3′ untranslated region, which presented a splicing from 3002 to 3170 but retained the sequence from intron 1 (129 bp). There was no structural alteration in the intron 1 sequence, the donor (gt) and the acceptor (ag) splicing regions were normal, and there was no mutation or microdeletion in the sequence matching HLA-B*1302 intron 1. We present the fi rst isolation of a cDNA for an HLA-B allele that retains intron 1 with no structural alteration in the sequence. It was previously reported that aberrant splicing of intron 1 by a 10 bp deletion near the 3′ end creates a novel null HLA-B*1501 allele. Studies are in progress to determine whether intron 1 is translated or deleted in a second round transfection of ANDO-2 cell line. The loss of a particular HLA allele within a given haplotype is a rare event. In a family study of a donor-recipient pair for a living kidney transplantation a recipient from the waiting list in Halle was found to bear an "HLA-B blank" haplotype. This "HLA-B blank" haplotype was inherited from the mother (donor) to her son (recipient). Due to the striking phenomenon all available individuals of the motherly site of the family were serologically HLA-typed by CDC and genetically by PCR-SSP and PCR-SBT techniques. Seven of 11 subjects seem to have a HLA-B deletion in the haplotype A*02; Cw*07; B*blank; MICA*00801g; DRB1*03; DQB1*02. To separate both haplotypes of one individual, lymphocytes from the mother and the MHC-identical brother were fused with the mouse myeloma cell line X63-Ag8.653. Colonies with a deletion in the HLA-B haplotype were tested with a set of 9 primer pairs to scan the region between MICA and HLA-B. A break point was found in the segment 42 kb telomeric from the MICA locus. Based on several sequence-entries (acc. No. AP000507, AP000508) and on the cell lines COX, PGF and C, primer sets were designed to fi nd the break point in the 81,2 kb region centromeric from HLA-Cw. In addition, both sequences telomeric and centromeric from HLA-B were monitored by microsatellite analyses with seven primer pairs. The existence of two different long amplicons in the genomic DNA could be verifi ed by Genome Walking. The HLA-B lacking haplotype was confi rmed to be maintained at least over three generations in this family. at least over three generations in this family.
